<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322308</url>
  </required_header>
  <id_info>
    <org_study_id>05-487</org_study_id>
    <nct_id>NCT01322308</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus</brief_title>
  <official_title>Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Institute, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart Institute, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to investigate the effect of pioglitazone (30 mg/day) on endothelial
      function in premenopausal women with SLE (systemic lupus erythematosus). Patients with
      hypertension, endocrine, hepatic or renal diseases will not be included, or pregnant /breast
      feeding women. This is a randomized, double blind, placebo controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SLE (systemic lupus erythematosus) is characterized by accelerated atherosclerosis. The risk
      of suffering an acute myocardial infarction among premenopausal women with SLE is 50 times
      higher than control women of the same age. Insulin resistance and hyperinsulinemia are
      frequent in SLE. Lipid metabolism in SLE, as in other insulin resistant states, is
      characterized by high triglycerides, low HDL-cholesterol, normal LDL cholesterol (or slightly
      increased) and an increase in LDL's susceptibility to oxidation.

      All these alterations can produce endothelial dysfunction which is present in SLE patients.
      Pioglitazone is a PPAR (peroxisome proliferator activated receptor) gamma agonist that can
      potentially improve insulin resistance, with a positive effect on the lipid profile (lowering
      of triglycerides, and a discrete increase in HDL-C) and improve endothelial function.

      Patients will be randomized to receive either placebo or pioglitazone 30 mg/day during a
      period of 12 weeks. Endothelial function will be assessed by Positron Emission Tomography
      (PET).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of endothelial function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Basal and final (12 weeks) endothelial function parameters measured by PET scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in HDL particle physicochemical characteristics</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL particle size, distribution and composition evaluated at baseline and at 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet similar to comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg tablets QD (taken once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>30 mg tablet QD (taken once daily)</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>actos</other_name>
    <other_name>zactos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet taken once a day</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible participants were premenopausal women with SLE

          -  Older than 18 years

          -  Attending the outpatient Rheumatology Clinic at three Mexico City community tertiary
             care hospitals

        Exclusion Criteria:

          -  menopause

          -  diabetes

          -  thyroid dysfunction

          -  neurological

          -  hepatic

          -  renal or liver disease

          -  personal history of high blood pressure

          -  CHD (coronary heart disease)

          -  cerebrovascular events

          -  chronic or acute infections

          -  malignancy

          -  nor history of chronic drugs or alcohol abuse

          -  smoking

          -  pregnancy or breast-feeding

          -  intake of hormones or lipid-regulating drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Posadas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of the Endocrinology Department</affiliation>
  </overall_official>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Heart Institute, Mexico</investigator_affiliation>
    <investigator_full_name>Nacu Caracas Portilla</investigator_full_name>
    <investigator_title>Juan Gabriel Juarez Rojas PhD</investigator_title>
  </responsible_party>
  <keyword>lupus</keyword>
  <keyword>HDL particles</keyword>
  <keyword>endothelial function</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

